Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Increases By 53.6%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 101,400 shares, a growth of 53.6% from the October 31st total of 66,000 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 139,700 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, Bolt Biotherapeutics has a consensus rating of “Hold” and an average target price of $3.50.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. purchased a new stake in Bolt Biotherapeutics in the 2nd quarter valued at $26,000. Acuitas Investments LLC raised its holdings in shares of Bolt Biotherapeutics by 21.7% in the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after purchasing an additional 112,555 shares during the last quarter. Finally, FMR LLC lifted its position in shares of Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares in the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock traded up $0.02 during trading hours on Friday, reaching $0.64. The company’s stock had a trading volume of 132,236 shares, compared to its average volume of 111,789. The stock’s fifty day simple moving average is $0.63 and its two-hundred day simple moving average is $0.69. Bolt Biotherapeutics has a one year low of $0.54 and a one year high of $1.56. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. On average, research analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.